Purine analogue combinations for indolent lymphomas.
Indolent lymphomas are a group of lymphoid malignancies with differing patterns of behavior and responses to treatment. The progress in treating patients with hairy cell leukemia (HCL) using nucleoside analogues can be used as a model for other indolent B-lymphoproliferative disorders, such as follicular lymphoma. Recent advancements in therapeutic options available for these patients include combination therapy with agents that have differing mechanisms of action and non-overlapping toxicity. It has been shown that patients who are candidates for aggressive therapy might receive benefit, including disease-free survival and overall survival, from combination purine analogue therapy. Using these more aggressive therapeutic approaches earlier in the disease course and as maintenance therapy may further enhance outcomes. With the advent of these new therapies along with the molecular evaluation of these regimens, we may be nearing the time where the goal for more advanced indolent lymphoma will be to achieve a cure.
Rocky Mountain Cancer Centers, Aurora, CO 80012, and Department of Leukemia, University of Texas, Houston, USA. nick.dibella@usoncology.com
Nicholas
N
Di Bella
Farhad
F
Ravandi
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D008223:Lymphoma / Q000145:classification / Q000188:drug therapy* / Q000401:mortality; D008224:Lymphoma, Follicular / Q000188:drug therapy; D011684:Purine Nucleosides / Q000627:therapeutic use*; D016896:Treatment Outcome
D011684:Purine Nucleosides